Setrobuvir

Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC50s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 RdRp and induces RdRp inhibition[1][2].

Product Specifications

CAS Number

1071517-39-9

Product Name Alternative

ANA598

UNSPSC

12352005

Target

DNA/RNA Synthesis; HCV; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/setrobuvir.html

Solubility

10 mM in DMSO

Smiles

CS(=O)(NC1=CC=C(C2=C1)N=C(C3=C(O)[C@]4([H])[C@@](C5)([H])CC[C@@]5([H])[C@]4([H])N(CC6=CC=C(F)C=C6)C3=O)NS2(=O)=O)=O

Molecular Formula

C25H25FN4O6S2

Molecular Weight

560.62

References & Citations

[1]Yi G, et al. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob Agents Chemother. 2012;56 (2) :830‐837.|[2]Elfiky AA. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silicoperspective [published online ahead of print, 2020 May 6]. J Biomol Struct Dyn. 2020;1‐9.